DOCK1 and hepatocellular carcinoma: Thus, we propose that HCC patients with low DOCK1 levels are recommended to metformin administration, while patients with high DOCK1 levels, which may lead to poor prognosis by activating DOCK1-RAC1 axis, should not be treated with metformin alone.